IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
about
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphomaCombination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaPerispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidenceCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Novel insights into the mechanism of action of lenalidomide.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Non-steady-state hematopoiesis regulated by the C/EBPβ transcription factor.Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic diseaseThe clinical significance of cereblon expression in multiple myeloma.The diverse roles of IRF4 in late germinal center B-cell differentiation.Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs.Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.Can we change the disease biology of multiple myeloma?Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.The Tao of myeloma.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Pomalidomide in the treatment of relapsed multiple myeloma.Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells.Trial Watch: Lenalidomide-based immunochemotherapy.Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.Immunotherapy Strategies Against Multiple Myeloma.Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma.Unraveling the multiple myeloma genome in the next-generation sequencing era: challenges to translating knowledge into the clinicIMiD compounds affect CD34 cell fate and maturation via CRBN-induced IKZF1 degradationImmunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturationSynergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
P2860
Q24614147-5E85E9AD-DF18-4B91-B3E2-0F20B61B5CEDQ27004421-F70E2A8C-8967-4780-BD64-A14502E9B883Q28649793-AD605A80-4C13-44D7-89CA-50F375916721Q33400424-06DF7AEC-DC39-4259-8107-B778C741769EQ33413142-45B6303A-8C80-4A30-8CE0-750987787981Q33947639-A948396B-BBFF-4D8E-9130-4EE6F5AFD812Q34210005-34C8E41C-F769-491E-B577-1FA1A5A20D38Q34253548-2185C10E-C5E0-4C3B-986D-AAE575D85FD7Q34373253-1D82A4C8-2C67-4A16-B258-C6A20A99415BQ35171777-71AE2142-1C8A-47C1-A754-0E83A46DEFD6Q35631319-E5D2AD71-88A4-42D2-9975-BA0DE1A61D01Q35784505-A84AE7D5-9AE1-435B-A4DD-EE3C84D0A627Q35904180-D9810397-8AD6-44F0-8481-972D8BF44D9AQ36090011-A59E1BC1-52A8-4EB7-99E4-4A077AE8C69EQ36141851-910D39D1-2CD9-48A6-8260-6DDCE0B8CA85Q36294841-01CD66B0-958C-4BA8-A5CC-C6F8D0ACB187Q36640589-CA9DEBB8-E832-4750-B17E-C5D94D5818EEQ36867284-A48DA604-6115-4783-B711-07A708EA083DQ37529076-7E37F9CB-3C12-4697-9016-B40D4CAEBCA9Q38002486-F2475676-4DC5-425F-ADD1-202B4F8FC641Q38012488-1D086A2F-0431-4929-B4D1-880433C444A6Q38042444-3D86FA31-4598-48B8-9870-0EEDAE7D6699Q38062038-8F9F1825-CC35-44BD-BB54-78A35EC5EB89Q38074017-E73DD92C-24AB-47BE-9155-F8055E3094E7Q38135264-5BEB24D7-373D-412C-8EFF-7A8436978078Q38237360-15040849-2DAD-4490-A816-10756093ED6DQ38462720-7F6FBE42-F15A-4FAB-BF92-5BD050085F57Q39138108-B86D00FE-16AD-47CD-94AC-107E8FF1CC80Q39388200-B5E46A6C-A090-4563-A898-A727C89CFA71Q42114228-605BBA16-7E08-4256-8D8C-6C69D2509F99Q42737828-7D89B1CE-CC57-4EC2-8D57-A9B418CE6DA6Q47096268-35BA2D7E-1898-4929-B24A-47A68D3DABF7Q49186472-11CA3412-B50F-4858-A900-5F5C03347D02Q49995864-F755D3FC-E653-4A3C-86B3-91B280F00321Q55359383-C9D74F20-1B8D-491B-9F48-022CC1DBC3E8Q58050756-6E2D19E6-C2AD-46D1-8162-EE4FED3CCDE5Q58299695-D7725FD2-D922-45D4-A9AE-14FA24522C5CQ58793871-C3FDF179-392A-4692-A9BB-76880BF8E2C1Q58801894-E63573AD-E031-459C-9FDF-136B320EB0C1
P2860
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
IMiD immunomodulatory compound ...... resulting in inhibition of MM.
@en
type
label
IMiD immunomodulatory compound ...... resulting in inhibition of MM.
@en
prefLabel
IMiD immunomodulatory compound ...... resulting in inhibition of MM.
@en
P2093
P2860
P1433
P1476
IMiD immunomodulatory compound ...... resulting in inhibition of MM
@en
P2093
Hongjiao Ouyang
Markus Mapara
Peter Schafer
Sara A Monaghan
Shirong Li
Suzanne Lentzsch
P2860
P304
P356
10.1182/BLOOD-2010-10-314278
P407
P577
2011-03-09T00:00:00Z